New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
09:10 EDTSUPNSupernus announces issuance of first use patents for SPN-812
Supernus Pharmaceuticals announced the issuance of a European patent and Canadian patent for SPN-812, its novel non-stimulant product candidate for the treatment of ADHD. These patents will provide protection for the product with expiration that is no earlier than 2029. Supernus has several additional patent applications for SPN-812 pending in other geographic regions, including the United States.
News For SUPN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
16:32 EDTSUPNSupernus sues TWi for infringement of Oxtellar XR patents
Subscribe for More Information
January 16, 2015
17:04 EDTSUPNSupernus sues Par Pharmaceuticals for patent infringement
Supernus Pharmaceuticals announced that it sued generic drug makers Par Pharmaceutical Companies, and Par Pharmaceutical, collectively known as Par, for infringement of four patents covering its antiepileptic drug Trokendi XR. Supernus' United States Patents Nos. 8,298,576, 8,298,580, 8,663,683 and 8,877,248 cover once-a-day topiramate formulations and methods of treating seizures using those formulations. Patent protection for Trokendi XR expires no earlier than 2027. The complaint, filed in the U.S. District Court for the District of New Jersey, alleges that Par infringed Supernus' Trokendi XR patents by submitting to the FDA an Abbreviated New Drug Application, ANDA, seeking to market a generic version of Trokendi XR prior to the expiration of Supernus' patents. Filing its complaint within 45 days of receiving Par's Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Par's ANDA for 30 months.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use